The Annual General Meeting 2022 was held on May 12th.
According to the decision made by the extraordinary general meeting on October 23, 2019, the nomination committee shall be appointed as follows:
The nomination committee shall consist of four members - one representative for each of the three largest shareholders as of the last banking day in September who wish to appoint a member of the nomination committee and the chairman of the board. In these instructions, the three largest shareholders refer to the owner-grouped registered shareholders or otherwise known shareholders as of the last banking day in September.
The chairman of the board must contact the three largest shareholders as soon as possible after the last banking day in September to find out if they wish to appoint members to the nomination committee. If one or some of the three largest shareholders refrain from appointing a member of the nomination committee, the chairman of the board must offer other major shareholders to appoint a member of the nomination committee. If such an offer is made, it shall go in order to the largest shareholders (ie first to the fourth largest shareholder, then to the fifth largest shareholder, etc.). The procedure shall continue until the selection committee consists of four members including the chairman of the board.
The nomination committee for the 2022 annual general meeting consisted of Rutger Arnhult (M2 Asset Management AB), Jan Ståhlberg (eget innehav), Linda Karlsson Engdahl, (Axel Karlsson) and Johan Bygge (chairman of the board).
Shareholders who wish to submit proposals to the Nomination Committee before the 2023 Annual General Meeting can do so via e-mail to: info@guardtherapeutics.com (head the e-mail with "The Nomination Committee") or by letter to the address: Guard Therapeutics AB, Att: Valberedningen, Box 5216, 102 45 Stockholm.